文献速递肿瘤 PET/CT

18F-FAPI-04 PET/CT在胰腺腺癌患者临床评估中优于18F-FDG PET/CT

18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.
PubMed 文献 · J Nucl Med · 2024-02-01

研究纳入62例胰腺导管腺癌(PDAC)患者,均行18F-FAPI-04 PET/CT与18F-FDG PET/CT检查。18F-FAPI-04在原发灶、淋巴结转移和远处转移的检出及TNM分期上均优于18F-FDG,原发灶SUVmax与全身治疗反应无相关性。

要点

  • 18F-FAPI-04 PET/CT检出全部62例PDAC原发灶,18F-FDG PET/CT漏诊1例。
  • 18F-FAPI-04在原发灶、淋巴结转移及肝、腹膜转移的摄取均高于18F-FDG。
  • 18F-FAPI-04较18F-FDG使14例分期上调、1例下调,N和M分期值显著更高。

核心结论

  • 18F-FAPI-04 PET/CT在PDAC原发灶、淋巴结转移和远处转移的识别及TNM分期方面均优于18F-FDG PET/CT。

研究设计与样本

  • 62例PDAC患者均接受18F-FAPI-04 PET/CT和18F-FDG PET/CT检查,评估原发灶、淋巴结转移和远处转移并完成TNM分期。
  • 在接受全身治疗的患者中探讨原发灶SUVmax与治疗反应的相关性。

主要发现

  • 18F-FAPI-04 PET/CT检出全部PDAC患者,18F-FDG PET/CT漏诊1例。
  • 原发灶摄取18F-FAPI-04为10.63,高于18F-FDG的2.87(P < 0.0001)。
  • 淋巴结转移摄取18F-FAPI-04为2.90,高于18F-FDG的1.43(P < 0.0001)。
  • 肝转移摄取18F-FAPI-04为6.11,高于18F-FDG的3.10(P = 0.002);腹膜转移为4.70 vs 2.08(P = 0.015)。
  • 两种方法T分期无显著差异,但18F-FAPI-04的N和M值显著高于18F-FDG(P = 0.002和0.008);18F-FAPI-04使14例分期上调、仅1例下调。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses associated with PDAC are often characterized by hypometabolism. Here, we investigated 18F-fibroblast activation protein inhibitor (FAPI)-04 PET/CT in evaluation of PDAC and compared the findings with those obtained using 18F-FDG. Methods: Sixty-two PDAC patients underwent 18F-FAPI-04 PET/CT and 18F-FDG PET/CT. Identification of primary lesions, lymph node (LN) metastasis, and distant metastasis (DM) by these methods was evaluated, and TNM staging was performed. Correlation between SUVmax of the primary lesion and treatment response was explored in patients who received systemic therapy. Results: 18F-FAPI-04 PET/CT identified all patients with PDAC; 18F-FDG PET/CT missed 1 patient. Tracer uptake was higher in 18F-FAPI-04 PET/CT than in 18F-FDG PET/CT in primary tumors (10.63 vs. 2.87, P < 0.0001), LN metastasis (2.90 vs. 1.43, P < 0.0001), and DM (liver, 6.11 vs. 3.10, P = 0.002; peritoneal, 4.70 vs. 2.08, P = 0.015). The methods showed no significant difference in the T staging category, but the N and M values were significantly higher for 18F-FAPI-04 PET/CT than for 18F-FDG PET/CT (P = 0.002 and 0.008, respectively). Thus, 14 patients were upgraded, and only 1 patient was downgraded, by 18F-FAPI-04 PET/CT compared with 18F-FDG PET/CT. A high SUVmax of the primary tumor did not correlate with treatment response for either 18F-FAPI-04 or 18F-FDG. Conclusion: 18F-FAPI-04 PET/CT performed better than 18F-FDG PET/CT in identification of primary tumors, LN metastasis, and DM and in TNM staging of PDAC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Li X, Lu N, Lin L, et al. 18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. J Nucl Med. 2024. PMID: 38176719. doi:10.2967/jnumed.123.266283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。